Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
Public ClinicalTrials.gov record NCT01232283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study will test efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
Study identification
- NCT ID
- NCT01232283
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 22, 2010 (Actual)
- Primary completion
- Mar 15, 2012 (Actual)
- Completion
- Nov 30, 2016 (Actual)
- Last update posted
- Mar 15, 2022
2010 – 2016
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Skin and Laser Therapy Inst., Ltd. | Phoenix | Arizona | 85023 | — |
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913 | — |
| Bakersfield Dermatology and Skin Cancer Medical Group | Bakersfield | California | 93309 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Clinical Science Institute | Santa Monica | California | 90404 | — |
| Florida Academic Dermatology Center | Miami | Florida | 33136 | — |
| Advanced Medical Research | Atlanta | Georgia | 30342 | — |
| MedaPhase Inc. | Newnan | Georgia | 30263 | — |
| Northwestern University Northwestern Medical Faculty Foundation | Chicago | Illinois | 60611 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| PMG Research of Winston-Salem | Winston-Salem | North Carolina | 27103 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27104 | — |
| Clinical Partners, LLC | Johnston | Rhode Island | 02919 | — |
| Radiant Research, Inc. | Anderson | South Carolina | 29560 | — |
| Austin Dermatology Associates | Austin | Texas | 78705 | — |
| Modern Research Associates PLLC | Dallas | Texas | 75231 | — |
| Center for Clinical Studies | Houston | Texas | 77004 | — |
| Center for Clinical Studies | Webster | Texas | 77598 | — |
| Virginia Medical Research | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01232283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2022 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01232283 live on ClinicalTrials.gov.